Last updated: August 14, 2026
Adalat is Bayer’s legacy nifedipine brand, marketed primarily for hypertension and angina. Its commercial profile has shifted from an innovative cardiovascular product to a mature, largely genericized medicine. Brand revenue is no longer separately disclosed by Bayer, while generic nifedipine extended-release products control most price-sensitive markets. The remaining value is concentrated in brand loyalty, specific modified-release formulations, hospital and specialty-channel supply, and geographic markets where branded medicines retain reimbursement or prescribing advantages.
What is Adalat and how is it positioned clinically?
Adalat contains nifedipine, a dihydropyridine calcium-channel blocker. Immediate-release and modified-release versions have been marketed under several names, including Adalat, Adalat CC, Adalat XL, and Adalat LA, depending on jurisdiction.
| Attribute |
Adalat profile |
| Active ingredient |
Nifedipine |
| Drug class |
Dihydropyridine calcium-channel blocker |
| Main indications |
Hypertension; chronic stable angina; vasospastic angina in applicable labels |
| Original innovator |
Bayer |
| Regulatory category |
Small-molecule prescription drug |
| Primary competition |
Generic nifedipine immediate-release and extended-release tablets |
| Biosimilar exposure |
None |
| Current commercial stage |
Mature, post-primary-exclusivity brand |
| Main value drivers |
Formulation, supply reliability, physician familiarity, local reimbursement |
The extended-release versions were designed to provide sustained nifedipine exposure and reduce the peak-related adverse effects associated with immediate-release dosing. Product differentiation therefore depends more on release technology, tablet performance, and regulatory interchangeability than on the active ingredient itself.
How has Adalat’s financial trajectory changed over time?
Adalat followed the standard financial pattern for a successful small-molecule cardiovascular brand: rapid uptake after launch, expansion through multiple dosage forms and markets, followed by sharp price and volume pressure after generic entry.
Commercial development
Nifedipine was introduced in the 1980s, when calcium-channel blockers were expanding in hypertension and ischemic heart disease. Adalat benefited from:
- A broad hypertension market.
- Use in chronic angina.
- Bayer’s international commercial infrastructure.
- Multiple formulations, including modified-release products.
- Long-term physician familiarity.
The brand reached maturity before the modern era of intensive generic substitution. Once generic nifedipine became available, prescribing shifted toward lower-cost alternatives, particularly in the United States and other markets with automatic substitution.
Bayer does not report Adalat revenue as a standalone line in current annual reporting. The product is included, where applicable, within broader pharmaceutical or legacy-product categories. This prevents a reliable current global brand-sales figure from being calculated from public company filings alone. Bayer’s financial reporting instead emphasizes major growth products and aggregate Pharmaceuticals performance. [1]
Financial trajectory
| Period |
Commercial condition |
Financial effect |
| 1980s to early 1990s |
Product expansion and cardiovascular adoption |
High-margin originator growth |
| Mid-1990s to early 2000s |
Modified-release products and wider generic awareness |
Continued volume, increasing defensive value of formulations |
| 2000s |
Generic entry in major markets |
Rapid erosion in U.S. branded sales and price |
| 2010s |
Mature generic market |
Lower brand revenue, stable residual demand |
| 2020s |
Commodity-like competition and fragmented regional branding |
Limited disclosed brand contribution; value tied to niche markets and supply execution |
Adalat is therefore unlikely to be a material growth driver for Bayer. Its economic role is more consistent with a mature cash-generating or portfolio-maintenance product than with a strategic growth asset.
What is the current market dynamic for Adalat and nifedipine?
The nifedipine market is driven by volume rather than innovation. Hypertension remains a large global disease category, but nifedipine competes against low-cost alternatives such as amlodipine, felodipine, and other antihypertensive classes.
Demand drivers
Demand remains supported by:
- High global prevalence of hypertension.
- Established clinical use of calcium-channel blockers.
- Nifedipine’s role in some pregnancy-related hypertension protocols and obstetric settings.
- Availability of extended-release dosage forms.
- Use in patients requiring a dihydropyridine calcium-channel blocker.
The market is constrained by:
- Generic substitution.
- Low unit prices.
- Competition from amlodipine, which often has simpler once-daily positioning and broad generic availability.
- Tender pricing in public healthcare systems.
- Prescriber movement toward guideline-preferred combinations.
- Limited differentiation between many generic extended-release products.
The World Health Organization identifies hypertension as a major global health burden and supports wider access to effective, affordable antihypertensive treatment. That expands the total treatment market but generally favors low-cost generic manufacturers rather than the Adalat brand. [2]
How does Adalat compare with amlodipine and other calcium-channel blockers?
Adalat competes clinically and commercially with drugs that have stronger current generic economics or broader prescribing penetration.
| Drug |
Commercial position |
Main competitive advantage over Adalat |
| Nifedipine ER |
Mature generic and legacy brand market |
Useful formulation and established clinical base |
| Amlodipine |
High-volume generic standard |
Long half-life, broad guideline use, simple once-daily dosing |
| Felodipine ER |
Smaller mature market |
Extended-release positioning |
| Diltiazem ER |
Generic rate-control and angina market |
Cardiac rate effects in selected patients |
| Verapamil ER |
Mature niche market |
Rate control and selected cardiovascular uses |
Amlodipine is the most important commercial comparator. Both drugs are dihydropyridine calcium-channel blockers, but amlodipine has achieved broad first-line use and strong generic penetration. Nifedipine retains clinical relevance in selected patients and settings, yet the brand does not have a durable pricing advantage over generic amlodipine or generic nifedipine.
What is the FDA regulatory status of Adalat?
Adalat and Adalat CC were approved as prescription products through new drug applications for nifedipine formulations. The FDA-approved labeling for Adalat CC identifies extended-release nifedipine tablets for hypertension and management of chronic stable angina in appropriate patients. [3]
The key regulatory distinction is between the brand product and generic abbreviated new drug applications:
- Brand approval establishes the reference product.
- Generic applicants may rely on the reference product through the ANDA pathway.
- Generic products must demonstrate pharmaceutical equivalence and bioequivalence.
- Extended-release products face formulation-specific performance requirements.
- Immediate-release and modified-release nifedipine products are not interchangeable solely because they contain the same active ingredient.
Brand availability can differ by country. A product may remain marketed as Adalat, Adalat XL, or Adalat LA in one jurisdiction while being discontinued, transferred, or replaced by a local licensee in another.
What is the Orange Book status of Adalat?
The FDA Orange Book identifies approved drug products and relevant patent or exclusivity information. For a mature product such as Adalat CC, the commercial significance of the listing is primarily regulatory reference status rather than active patent exclusivity.
The relevant U.S. product information includes:
| U.S. product |
Active ingredient |
Dosage form |
Regulatory significance |
| Adalat CC |
Nifedipine |
Extended-release tablet |
Reference product for generic competition |
| Generic nifedipine ER |
Nifedipine |
Extended-release tablet |
ANDA-based competition |
| Immediate-release nifedipine products |
Nifedipine |
Capsule or tablet, depending on product |
Separate formulation and substitution analysis |
The Orange Book must be evaluated by specific NDA, strength, dosage form, and listed patent status. A historical patent associated with an Adalat formulation does not create a current monopoly over all nifedipine products. [4]
What patents protect Adalat and when did exclusivity expire?
Adalat’s principal composition-of-matter protection expired long ago. Current commercial protection, where it exists, is formulation-based, trademark-based, or dependent on country-specific regulatory rights rather than a broad active-ingredient patent.
Patent protection by category
| Protection category |
Relevance to Adalat |
| Nifedipine compound patent |
Expired |
| Original formulation patents |
Expired or commercially exhausted in major markets |
| Modified-release formulation patents |
Historically important; major barriers have expired |
| Manufacturing patents |
May remain confidential or jurisdiction-specific, but rarely sustain brand-level exclusivity alone |
| Method-of-use patents |
May exist in specific jurisdictions, but do not broadly protect the molecule |
| Trademark rights |
Can remain valuable after patent expiry |
| Regulatory exclusivity |
No meaningful current new-product exclusivity comparable to an innovative launch |
Adalat’s U.S. generic-entry risk materialized after the expiry or loss of enforceability of relevant formulation protection. By the 2000s, generic nifedipine products were available in major markets, and the brand’s ability to maintain premium pricing declined materially.
No current broad patent estate is generally understood to block generic nifedipine across the U.S. market. Patent status must still be checked at the product and jurisdiction level because release mechanisms, manufacturing processes, and local formulations can have separate rights.
Which companies compete with Adalat?
Competition is fragmented. It includes large generic companies, regional manufacturers, and local distributors.
Competitive groups
- Teva and other multinational generic companies.
- Sandoz and Viatris in markets where their nifedipine products are approved.
- Regional manufacturers in Europe, Asia, Latin America, and the Middle East.
- Hospital and tender suppliers offering generic nifedipine extended-release products.
- Local licensees marketing nifedipine under country-specific brands.
The competitive landscape is usually determined by regulatory approval, supply reliability, tender access, and manufacturing cost. Brand advertising has limited influence in markets where substitution is automatic or pharmacy procurement is centralized.
What generic entry risks exist for Adalat?
Generic entry risk is structural rather than prospective. Adalat has already experienced the principal loss-of-exclusivity event in major markets.
Generic launch scenarios
| Scenario |
Probability |
Commercial impact |
| Additional generic entrants |
High in underpenetrated markets |
Further price compression |
| Brand retention at a premium |
Low to moderate, market-dependent |
Preserves niche revenue but not broad growth |
| Supply disruption among generics |
Moderate |
Temporary volume recovery or price stabilization |
| New branded nifedipine formulation |
Low |
Requires meaningful clinical or delivery differentiation |
| Conversion to hospital or specialty niches |
Moderate |
Stabilizes selected segments |
The largest risk is not a new Paragraph IV challenge to a valuable active patent. It is continuing erosion from approved generic alternatives, procurement substitution, and lower reimbursement. A Paragraph IV filing against an active formulation patent would have had significance during the original exclusivity period, but it is unlikely to alter the present global commercial position materially.
What formulation patents and manufacturing barriers remain?
Modified-release nifedipine products can involve technically sensitive manufacturing steps, including:
- Drug-polymer matrix design.
- Coating and dissolution control.
- Dose uniformity.
- Stability under heat and humidity.
- Scale-up of release kinetics.
- Bioequivalence across strengths.
- Packaging that protects tablets from environmental degradation.
These barriers can delay or limit individual generic entrants, but they do not usually protect the Adalat brand from mature-market competition. A manufacturer may need formulation development and comparative dissolution data even when no blocking patent remains.
Manufacturing risk has become more important than patent risk. Nifedipine supply can be affected by active pharmaceutical ingredient concentration, limited qualified suppliers, regulatory inspections, and low-margin production decisions. In a low-priced market, manufacturers may exit if reimbursement falls below sustainable levels.
What patent litigation and settlement agreements affect Adalat?
Adalat’s major litigation relevance was associated with historical generic challenges to nifedipine formulations. The economic effect of those disputes has largely passed because the underlying exclusivity periods expired years ago.
There is no broadly material current U.S. litigation posture comparable to the patent disputes surrounding newer oncology, immunology, or diabetes products. Settlement agreements, where entered historically, would have affected the timing of generic entry during the relevant patent period. They do not restore present-day brand exclusivity.
The main legal exposures now are more likely to involve:
- Trademark use.
- Product liability.
- Regulatory compliance.
- Manufacturing quality.
- Distribution rights.
- Local licensing and commercialization agreements.
- False or misleading substitution claims.
Does Adalat face biosimilar risk?
No. Adalat is a chemically synthesized small molecule, not a biologic. Biosimilar regulation does not apply. Its competitive threat comes from conventional generic drugs approved through ANDAs or equivalent national procedures.
This distinction matters commercially. Generic nifedipine applicants do not need to replicate the biologic development and interchangeability framework used for products such as monoclonal antibodies. The result is lower development cost, a larger potential supplier base, and more severe price competition.
What licensing deals and geographic coverage matter?
Adalat has historically been commercialized through Bayer’s own operations and regional arrangements. Rights, trademarks, dosage forms, and distributors can vary by country. A single global revenue estimate is therefore unreliable without product-level sales data from each local entity.
Geographic commercial profile
| Region |
Market condition |
| United States |
Generic-dominated; residual brand value limited |
| Western Europe |
Strong generic substitution and national reimbursement controls |
| United Kingdom |
Brand and formulation naming can differ; generic competition is established |
| Japan |
Local regulatory and commercial structures affect brand positioning |
| China and other Asian markets |
High volume potential, intense local competition, tender pressure |
| Latin America |
Mixed branded-generic market; distributor and reimbursement differences |
| Middle East and Africa |
Brand recognition may persist, but access depends on procurement and affordability |
Geographic coverage is commercially relevant because Adalat’s residual value may be higher in markets where physicians prescribe by brand or where generic penetration is incomplete. Those advantages are generally vulnerable to government tenders, local manufacturing, and reimbursement reform.
How strong is the Adalat patent estate?
Adalat’s current patent estate is weak as a source of exclusivity. The active ingredient is long off patent, and the principal modified-release technologies have been exposed to generic competition for many years.
| Estate element |
Current strength |
| Compound patent |
None of practical commercial relevance |
| Core product patent |
Expired |
| Extended-release formulation protection |
Historically important, now limited |
| Manufacturing know-how |
Potentially useful but difficult to monetize as exclusivity |
| Trademark |
Moderate in selected markets |
| Regulatory position |
Reference-product value remains |
| Litigation leverage |
Low relative to active innovative brands |
The strongest remaining assets are brand recognition, regulatory history, manufacturing knowledge, and channel relationships. Those assets can support steady residual sales but do not support a high-growth valuation.
What is the commercial outlook and revenue exposure for Adalat?
Adalat’s revenue outlook is stable to declining, with upside dependent on supply shortages, regional brand preference, or portfolio transactions rather than market expansion. The product is unlikely to materially affect Bayer’s consolidated growth profile.
Base-case outlook
- Continued generic volume dominance.
- Low or negative real-price growth.
- Brand retention in selected markets.
- Limited marketing investment.
- Ongoing pressure from amlodipine and other generic antihypertensives.
- Revenue concentration in countries with weaker substitution or established Adalat prescribing.
Upside factors
- Generic supply interruptions.
- Reimbursement preference for the branded product.
- Increased use of nifedipine ER in selected hypertension or obstetric settings.
- Successful local licensing or distribution arrangements.
Downside factors
- Additional generic approvals.
- Mandatory substitution.
- Product discontinuation in low-volume markets.
- Manufacturing compliance events.
- Tender losses.
- Physician migration to amlodipine or combination therapies.
Key Takeaways
- Adalat is a mature nifedipine brand with no meaningful active-ingredient exclusivity.
- Generic competition, not Paragraph IV litigation, is the dominant commercial risk.
- Bayer does not disclose current standalone Adalat revenue, preventing a precise global brand-sales estimate from public filings.
- Adalat’s remaining value is concentrated in formulation familiarity, trademarks, distribution, and selected geographic markets.
- The product has no biosimilar exposure because nifedipine is a small molecule.
- Extended-release formulation and manufacturing complexity can limit individual generic entrants but do not create durable brand-level exclusivity.
- Revenue is expected to remain modest and mature, with downside from substitution and tender pricing.
- The strongest commercial comparator is generic amlodipine, which generally has broader first-line use and stronger current market penetration.
FAQs About Adalat Market Position and Exclusivity
Is Adalat still sold in the United States?
Availability depends on the specific Adalat product and channel. Generic nifedipine ER products are widely used, while branded availability may be limited or discontinued in particular markets.
Is Adalat more profitable than generic nifedipine?
The brand can command a higher unit price, but its lower volume and distribution costs reduce the overall commercial advantage. Generic nifedipine controls most price-sensitive demand.
Can a generic manufacturer launch nifedipine without challenging Adalat patents?
Yes. After expiration or removal of relevant formulation patents, an applicant can pursue approval through the applicable generic pathway without a Paragraph IV challenge to a blocking patent.
Does Adalat have pediatric exclusivity or orphan-drug exclusivity?
No current pediatric or orphan exclusivity is generally associated with the mature Adalat product. Its principal commercial rights derive from approval, trademarks, and local market authorization.
Could Bayer sell or license Adalat to another company?
Yes. Mature cardiovascular brands are commonly transferred or licensed where a buyer values regional distribution, regulatory approvals, or established prescriber demand. Such a transaction would be a portfolio-management event rather than a patent-driven deal.
References
- Bayer AG. (2024). Annual report 2023. Bayer AG.
- World Health Organization. (2023). Global report on hypertension: The race against a silent killer. World Health Organization.
- U.S. Food and Drug Administration. (2016). Adalat CC (nifedipine) extended-release tablets: Prescribing information. FDA.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
